Retrospective cohort study shows associations of enfortumab vedotin and pembrolizumab with survival in urothelial cancer, suggesting treatment continuity may improve outcomes.
This retrospective cohort study examines the association of upfront treatment with enfortumab vedotin plus pembrolizumab with clinical outcomes for patients with advanced urothelial cancer.
No takes yet. Share an insight, caveat, or question.
Chow et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: